Gokila. Shanmuganathan, Anandhi. D, R. K, V. Subban, A. Mullasari, S. Kumaran, Chitrashree. V, Harini Anandan
{"title":"Clinical Outcomes of Patients with Type II Diabetes Mellitus and Hypothyroidism undergoing Percutaneous Coronary Revascularization","authors":"Gokila. Shanmuganathan, Anandhi. D, R. K, V. Subban, A. Mullasari, S. Kumaran, Chitrashree. V, Harini Anandan","doi":"10.13005/bpj/2694","DOIUrl":null,"url":null,"abstract":"Background: Diabetes mellitus (DM) and hypothyroidism are independently associated with coronary artery disease (CAD) severity with poor percutaneous revascularization outcomes. However, the influence of Type II diabetes mellitus (T2DM) with hypothyroidism on the clinical outcomes of patients undergoing percutaneous coronary intervention (PCI) has not been evaluated. Aim: The aim of the study is to assess the clinical outcomes of CAD patients with T2DM and hypothyroidism undergoing PCI. Materials and Methods: Consecutive patients who underwent PCI from September 2020 to March 2021 at our institution were enrolled in the study. Patients were categorized into four groups: Group I-Patients with euglycemia and euthyroid, Group II- patients with T2DM and euthyroid, Group III- patients with hypothyroidism and euglycemic, and Group IV- Patients with T2DM and hypothyroidism. Baseline demographics, laboratory investigations, procedural details, and in-hospital major adverse cardiovascular events were assessed. The continuous and normally distributed data were presented as mean ± standard deviation and were analysed using ANOVA. Categorical data were presented as the frequency with percentages and analysed using the Chi-square test. Result: In the total of 605 patients, 36% (n=220), 54% (n=325), 3% (n=19), and 7% (n=41) were in Group I, Group II, Group III, and Group IV respectively. The mean age of the population was 56.1 ± 11.6 vs 59.6 ± 9.8 vs 60.4 ± 9.9 vs 56.9 ± 12.1 (p = 0.002). Males were predominant 89.5% (n=197) in Group I and females were predominant 47.4% (n=9) in Group III. The prevalence of hypertension and dyslipidemia were high in Group II and Group IV respectively. Higher triglyceride levels (159.6 ± 109.6 Vs 166.2 ± 83.2 Vs 136.7 ± 72.3 Vs 222.2 ± 161.9, p = 0.03) and glycosylated hemoglobin A1c (HbA1C) levels (6.2 ± 1.2 Vs 8.5 ± 1.9 Vs 6.6 ± 2.1 Vs 9.2 ± 1.8, p<0.001) were noted in Group IV. Single vessel disease was high (59.1% Vs 45.5% Vs 57.8% Vs 48.7%, p=0.02) among Group I patients whereas left anterior descending (LAD) artery involvement was more in Group IV (64.5% Vs 57.8% Vs 36.8% Vs 70.7%, p=0.03) and in-stent restenosis was high among Group III (0.9% Vs 3.7% Vs 10.5%, p=0.02). Incidence of bleeding was high in Group III (0.5% Vs 1.2% Vs 10.5%, p= 0.001). There was no significant difference in In-hospital mortality between groups. Conclusion: Patients with T2DM and hypothyroidism had significantly higher levels of triglycerides, HbA1C and more LAD involvement but there was no significant difference in in- hospital mortality.","PeriodicalId":9054,"journal":{"name":"Biomedical and Pharmacology Journal","volume":"76 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biomedical and Pharmacology Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.13005/bpj/2694","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Diabetes mellitus (DM) and hypothyroidism are independently associated with coronary artery disease (CAD) severity with poor percutaneous revascularization outcomes. However, the influence of Type II diabetes mellitus (T2DM) with hypothyroidism on the clinical outcomes of patients undergoing percutaneous coronary intervention (PCI) has not been evaluated. Aim: The aim of the study is to assess the clinical outcomes of CAD patients with T2DM and hypothyroidism undergoing PCI. Materials and Methods: Consecutive patients who underwent PCI from September 2020 to March 2021 at our institution were enrolled in the study. Patients were categorized into four groups: Group I-Patients with euglycemia and euthyroid, Group II- patients with T2DM and euthyroid, Group III- patients with hypothyroidism and euglycemic, and Group IV- Patients with T2DM and hypothyroidism. Baseline demographics, laboratory investigations, procedural details, and in-hospital major adverse cardiovascular events were assessed. The continuous and normally distributed data were presented as mean ± standard deviation and were analysed using ANOVA. Categorical data were presented as the frequency with percentages and analysed using the Chi-square test. Result: In the total of 605 patients, 36% (n=220), 54% (n=325), 3% (n=19), and 7% (n=41) were in Group I, Group II, Group III, and Group IV respectively. The mean age of the population was 56.1 ± 11.6 vs 59.6 ± 9.8 vs 60.4 ± 9.9 vs 56.9 ± 12.1 (p = 0.002). Males were predominant 89.5% (n=197) in Group I and females were predominant 47.4% (n=9) in Group III. The prevalence of hypertension and dyslipidemia were high in Group II and Group IV respectively. Higher triglyceride levels (159.6 ± 109.6 Vs 166.2 ± 83.2 Vs 136.7 ± 72.3 Vs 222.2 ± 161.9, p = 0.03) and glycosylated hemoglobin A1c (HbA1C) levels (6.2 ± 1.2 Vs 8.5 ± 1.9 Vs 6.6 ± 2.1 Vs 9.2 ± 1.8, p<0.001) were noted in Group IV. Single vessel disease was high (59.1% Vs 45.5% Vs 57.8% Vs 48.7%, p=0.02) among Group I patients whereas left anterior descending (LAD) artery involvement was more in Group IV (64.5% Vs 57.8% Vs 36.8% Vs 70.7%, p=0.03) and in-stent restenosis was high among Group III (0.9% Vs 3.7% Vs 10.5%, p=0.02). Incidence of bleeding was high in Group III (0.5% Vs 1.2% Vs 10.5%, p= 0.001). There was no significant difference in In-hospital mortality between groups. Conclusion: Patients with T2DM and hypothyroidism had significantly higher levels of triglycerides, HbA1C and more LAD involvement but there was no significant difference in in- hospital mortality.
背景:糖尿病(DM)和甲状腺功能减退与冠状动脉疾病(CAD)严重程度和不良经皮血运重建结果独立相关。然而,2型糖尿病(T2DM)合并甲状腺功能减退对经皮冠状动脉介入治疗(PCI)患者临床结局的影响尚未得到评估。目的:本研究的目的是评估冠心病合并2型糖尿病和甲状腺功能减退患者行PCI治疗的临床结果。材料和方法:2020年9月至2021年3月在我院连续接受PCI治疗的患者纳入研究。将患者分为四组:ⅰ组血糖正常且甲状腺功能正常,ⅱ组(T2DM合并甲状腺功能正常),ⅲ组(甲状腺功能减退且血糖正常),ⅳ组(T2DM合并甲状腺功能减退)。基线人口统计学、实验室调查、程序细节和院内主要不良心血管事件进行了评估。连续和正态分布的数据以均数±标准差表示,并使用方差分析进行分析。分类数据以频率和百分比表示,并使用卡方检验进行分析。结果:605例患者中,I、II、III、IV组分别占36%(220例)、54%(325例)、3%(19例)、7%(41例)。人群平均年龄为56.1±11.6 vs 59.6±9.8 vs 60.4±9.9 vs 56.9±12.1 (p = 0.002)。ⅰ组男性占89.5% (n=197),ⅲ组女性占47.4% (n=9)。高血压和血脂异常的患病率分别在II组和IV组较高。高甘油三酸酯水平(159.6±109.6 Vs 166.2±83.2 Vs 136.7±72.3 Vs 222.2±161.9,p = 0.03)和糖化血红蛋白糖化血红蛋白(HbA1C)水平(6.2±1.2 Vs 8.5±1.9 Vs 6.6±2.1 Vs 9.2±1.8,p < 0.001)被发现在第四组,单船疾病高(59.1% Vs 45.5% Vs 57.8%比48.7%,p = 0.02)在组我左冠状动脉前降(小伙子)病人而参与更多的是在第四组(64.5% Vs 57.8% Vs 36.8% Vs 70.7%,p=0.03),支架内再狭窄发生率较高(0.9% Vs 3.7% Vs 10.5%, p=0.02)。III组出血发生率高(0.5% Vs 1.2% Vs 10.5%, p= 0.001)。两组住院死亡率无显著差异。结论:T2DM合并甲状腺功能减退患者的甘油三酯、糖化血红蛋白水平和LAD累及程度均显著升高,但住院死亡率无显著差异。
期刊介绍:
Biomedical and Pharmacology Journal (BPJ) is an International Peer Reviewed Research Journal in English language whose frequency is quarterly. The journal seeks to promote research, exchange of scientific information, consideration of regulatory mechanisms that affect drug development and utilization, and medical education. BPJ take much care in making your article published without much delay with your kind cooperation and support. Research papers, review articles, short communications, news are welcomed provided they demonstrate new findings of relevance to the field as a whole. All articles will be peer-reviewed and will find a place in Biomedical and Pharmacology Journal based on the merit and innovativeness of the research work. BPJ hopes that Researchers, Research scholars, Academician, Industrialists etc. would make use of this journal for the development of science and technology. Topics of interest include, but are not limited to: Biochemistry Genetics Microbiology and virology Molecular, cellular and cancer biology Neurosciences Pharmacology Drug Discovery Cardiovascular Pharmacology Neuropharmacology Molecular & Cellular Mechanisms Immunology & Inflammation Pharmacy.